Regarding the U.S. Sales Partnership with Terrain for “Bondlido” and Launch Timing

Progress of Partnership and Launch Preparations

Regarding Bondlido, a lidocaine patch product for the U.S. market, MedRx Co., Ltd is finalizing the contractual conditions for a U.S. sales license with Terrain Pharmaceuticals, and finalizing those contract terms is taking additional time. As of September 30, the expected execution has been revised to within 2026, and the initial shipment is scheduled to be delivered to Terrain in November. Launch preparations are progressing in parallel, and the expected launch timing remains within 2026.

Market Outlook, Impact and Next Steps

Bondlido is a novel lidocaine topical patch using ILTS technology, and synergistic effects in the U.S. market are anticipated. Assuming future increases in sales volume, the contract terms are expected to reflect provisions for increased production and cost-sharing. At this time, the impact on the fiscal year ending December 2026 is expected to be minimal, and launch preparations and the start of sales will proceed in parallel.